Amphastar Pharmaceuticals, Inc. reported net revenues of $170.5 million for the first quarter ended March 31, 2025, which was flat year-over-year. GAAP net income for the quarter was $25.3 million, or $0.51 per diluted share, while adjusted non-GAAP net income reached $36.9 million, or $0.74 per diluted share, beating analysts' consensus estimates.
Dr. Jack Zhang, President and CEO, expressed confidence in the potential of the company's portfolio, particularly with the growth of BAQSIMI and Primatene MIST, and the promising pipeline of biosimilars and proprietary products. Management attributed flat revenue to ongoing competition in critical care products like Glucagon and Epinephrine.
The company is navigating an 'inflection year' with flat revenue growth and declining profits, but anticipates a return to double-digit growth rates in 2026. This future growth is expected to be driven by upcoming product launches and continued momentum from branded products, aligning with its strategic transformation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.